Literature DB >> 9284264

Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease.

D Y Leung1, K E Sullivan, T F Brown-Whitehorn, A P Fehringer, S Allen, T H Finkel, R L Washington, R Makida, P M Schlievert.   

Abstract

Kawasaki syndrome (KS) has been reported to be associated with selective expansion of Vbeta2+ T cells and either staphylococcal toxic shock syndrome toxin-1 or streptococcal pyrogenic exotoxin C in uncomplicated cases. However, there have been no previous studies on the role of superantigens in KS associated with coronary artery disease, the major complication of this illness. The present study characterized bacteria isolated from three acute KS patients who developed coronary artery disease. Staphylococcus aureus secreting either TSST-1 (n = 3) or exfoliative toxin A (n = 1), both known to stimulate expansion of Vbeta2+ T cells, were isolated from all three patients. The percent Vbeta2+ T cells was determined in three patients with coronary artery disease. On presentation, one patient demonstrated reduction, whereas the other two showed expansion, of Vbeta2+ T cells. Repeat analyses of the latter two children showed their percent Vbeta2+ T cells to decrease toward normal. These observations suggest that coronary artery disease in KS may result from superantigenic stimulation of Vbeta2+ T cells. This is also the first demonstration of an association of staphylococcal exfoliative toxin with acute KS. The observation that three different bacterial toxins associated with KS are potent activators of Vbeta2+ T cells suggests an important role for this T cell subset in the pathogenesis of this autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284264     DOI: 10.1203/00006450-199709000-00004

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A.

Authors:  E R Wann; A P Fehringer; Y V Ezepchuk; P M Schlievert; P Bina; R F Reiser; M M Höök; D Y Leung
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.

Authors:  K Riesbeck; A Billström; J Tordsson; T Brodin; K Kristensson; M Dohlsten
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

4.  Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis.

Authors:  E R Popa; C A Stegeman; N A Bos; C G M Kallenberg; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

Review 5.  Staphylococcal and streptococcal superantigen exotoxins.

Authors:  Adam R Spaulding; Wilmara Salgado-Pabón; Petra L Kohler; Alexander R Horswill; Donald Y M Leung; Patrick M Schlievert
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 6.  Staphylococcus aureus and Wegener's granulomatosis.

Authors:  Eliane R Popa; Coen A Stegeman; Cees G M Kallenberg; Jan Willem Cohen Tervaert
Journal:  Arthritis Res       Date:  2001-10-26

7.  Case report of an unusual presentation of Staphylococcus aureus induced toxic shock syndrome/hyperimmunoglobulinemia E syndrome.

Authors:  Harry S Jacob; Gregory M Vercellotti; Donald Y M Leung; Patrick M Schlievert
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.